ZA201803097B - High-dose statins for age-related macular degeneration - Google Patents

High-dose statins for age-related macular degeneration

Info

Publication number
ZA201803097B
ZA201803097B ZA2018/03097A ZA201803097A ZA201803097B ZA 201803097 B ZA201803097 B ZA 201803097B ZA 2018/03097 A ZA2018/03097 A ZA 2018/03097A ZA 201803097 A ZA201803097 A ZA 201803097A ZA 201803097 B ZA201803097 B ZA 201803097B
Authority
ZA
South Africa
Prior art keywords
age
macular degeneration
related macular
dose statins
statins
Prior art date
Application number
ZA2018/03097A
Other languages
English (en)
Inventor
Demetrios Vavvas
Joan W Miller
Original Assignee
Massachusetts Eye & Ear Infirmary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye & Ear Infirmary filed Critical Massachusetts Eye & Ear Infirmary
Publication of ZA201803097B publication Critical patent/ZA201803097B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA2018/03097A 2015-10-14 2018-05-11 High-dose statins for age-related macular degeneration ZA201803097B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562241522P 2015-10-14 2015-10-14
PCT/US2016/056987 WO2017066529A1 (en) 2015-10-14 2016-10-14 High-dose statins for age-related macular degeneration

Publications (1)

Publication Number Publication Date
ZA201803097B true ZA201803097B (en) 2022-12-21

Family

ID=58517927

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/03097A ZA201803097B (en) 2015-10-14 2018-05-11 High-dose statins for age-related macular degeneration

Country Status (13)

Country Link
US (2) US11331295B2 (enExample)
EP (1) EP3362063B1 (enExample)
JP (3) JP7037186B2 (enExample)
AU (1) AU2016338540B2 (enExample)
CA (1) CA3001661C (enExample)
DK (1) DK3362063T3 (enExample)
ES (1) ES2941347T3 (enExample)
FI (1) FI3362063T3 (enExample)
IL (1) IL258604B2 (enExample)
MX (1) MX391944B (enExample)
PH (1) PH12018500745B1 (enExample)
WO (1) WO2017066529A1 (enExample)
ZA (1) ZA201803097B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11789024B2 (en) 2017-05-09 2023-10-17 Massachusetts Eye And Ear Infirmary Biomarkers for age-related macular degeneration
WO2019018350A1 (en) * 2017-07-17 2019-01-24 Keith Roizman TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES
US20200243170A1 (en) * 2017-10-17 2020-07-30 Apeliotus Technologies, Inc. Functional biomarkers for statin therapy in age-related macular degeneration (amd)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030065020A1 (en) * 2001-07-13 2003-04-03 Catharine Gale Treatment of macular degeneration
CA2478317A1 (en) 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
WO2005083430A1 (en) 2004-02-25 2005-09-09 Massachusetts Eye & Ear Infirmary Biomarkers for age-related macular degeneration (amd)
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006083533A2 (en) * 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
WO2008006535A2 (en) 2006-07-10 2008-01-17 Medigene Ag Use of a cationic colloidal preparation for the diagnosis and treatment of ocular diseases
JP2008268506A (ja) * 2007-04-19 2008-11-06 Fuji Xerox Co Ltd 現像装置、像保持体ユニットおよび画像形成装置
WO2009023411A1 (en) 2007-08-09 2009-02-19 Bausch & Lomb Incorporated Compositions and methods for treating or controlling anterior- and posterior-segment ophthalmic diseases
US20120156202A1 (en) 2010-11-05 2012-06-21 Shantha Totada R Age related macular degeneration treatment
ES2947557T3 (es) 2013-09-06 2023-08-11 Vanda Pharmaceuticals Inc Tratamiento de afecciones mediadas por CYR61 y VEGF
WO2016009430A1 (en) 2014-07-14 2016-01-21 Yeda Research And Development Co. Ltd Reduction of aging-induced type i interferon signaling at the brain's choroid plexus or within the cns for treatment of disease or injury of the cns
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol

Also Published As

Publication number Publication date
CA3001661A1 (en) 2017-04-20
DK3362063T3 (da) 2023-04-03
EP3362063A4 (en) 2019-06-19
PH12018500745B1 (en) 2023-03-15
AU2016338540A1 (en) 2018-05-24
EP3362063A1 (en) 2018-08-22
AU2016338540B2 (en) 2022-04-28
US20190209522A1 (en) 2019-07-11
JP2024016045A (ja) 2024-02-06
IL258604B1 (en) 2024-05-01
US11331295B2 (en) 2022-05-17
EP3362063B1 (en) 2023-01-11
NZ742203A (en) 2025-06-27
JP7754480B2 (ja) 2025-10-15
MX2018004636A (es) 2019-06-20
JP2022003042A (ja) 2022-01-11
IL258604B2 (en) 2024-09-01
US11744817B2 (en) 2023-09-05
WO2017066529A1 (en) 2017-04-20
JP2018530586A (ja) 2018-10-18
US20210077457A1 (en) 2021-03-18
ES2941347T3 (es) 2023-05-22
IL258604A (en) 2018-06-28
JP7037186B2 (ja) 2022-03-16
FI3362063T3 (fi) 2023-04-06
PH12018500745A1 (en) 2018-10-15
MX391944B (es) 2025-03-21
CA3001661C (en) 2025-05-06

Similar Documents

Publication Publication Date Title
DK3478217T3 (en) Historisk scanningsreference for intraorale scanninger
IL239836A0 (en) Treatment of age-related macular degeneration
IL248400B (en) Compounds and preparations for inducing cartilage formation
IL248779A0 (en) Pharmaceutical preparations for the treatment of infectious diseases
SG11201606101WA (en) Compositions and methods for treating and preventing macular degeneration
EP3174540A4 (en) Methotrexate for proliferative vitreoretinopathy
ZA201904051B (en) Peptide for treating age-related macular degeneration
ZA201701734B (en) Conjugate for treating malaria
IL257264A (en) Consequence of piperazine
GB201616158D0 (en) Age-related macular degeneration
ZA201803097B (en) High-dose statins for age-related macular degeneration
ZA201802194B (en) Aminoazole derivative
ZA201700112B (en) Pharmaceutical for treating dizziness having different causes
SG11201800022VA (en) Method for killing spores
GB201508877D0 (en) Patient checklist for orthapaedics
ZA201608098B (en) Sprung mattress
HUE055659T2 (hu) Emulziók injektálható készítményekhez
GB201518394D0 (en) Apparatus for securing two members together
GB201517431D0 (en) Apparatus for securing two members together
GB201520110D0 (en) Carton
GB201515463D0 (en) Staples
HUP1500171A2 (en) Wheel for grass-mower
HUP1500021A1 (hu) Modulált excenter hajtómû